Exhibit 99.1
Telesis Bio Appoints William J. Kullback Chief Financial Officer
SAN DIEGO, August 29, 2023 (GLOBE NEWSWIRE) Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has
named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Companys financial planning and analysis, accounting, internal audit, tax, and treasury functions.
Bills deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to help lead us through the
next phase of the Companys growth, said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. We are thrilled to welcome Bill to our team and excited to have another leader who brings both a strategic and operational mindset to
creating shareholder value as we deliver researchers the tools they need to rapidly and securely design, code, and create synthetic DNA and RNA.
With more than twenty-eight years of experience as a Chief Financial Officer, Mr. Kullback has held a broad range of financial management and operational
roles, primarily in mid-sized to large corporations, including multiple publicly held life-science companies.
Prior to joining Telesis Bio, Mr. Kullback served for five plus years as CFO of BioLegend, Inc., a worldwide provider of life science antibodies and
reagents, where he led the companys September 2021 sale to NYSE listed Revvity (formerly PerkinElmer) for $5.25 billion, the largest acquisition in PerkinElmers history.
Before joining BioLegend in 2017, Mr. Kullback served as Chief Financial Officer of Lombard Medical, Inc. (Nasdaq: EVAR), a medical device company, from
2014 to 2017, prior to its acquisition by MicroPort Scientific Corporation, a Shanghai, China based medical device group. Similar CFO appointments at other medical device and technology companies have resulted in a host of successful transactions
involving debt, M&A buy-side, M&A sell-side, and public offerings.
Mr. Kullback earned both his MBA
and bachelors degree from the State University of New York at Buffalo.
About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanitys greatest challenges. As
inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible
writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a
result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.